Public Citizen, a consumer advocacy group, is urging the FDA to strengthen its warnings that SGLT-2 inhibitors are associated with increased risk of diabetic ketoacidosis, due to hundreds of cases of this potentially fatal condition in people with type 1 diabetes. SGLT-2 inhibitors are not currently approved for use in type 1 diabetes in the US. Read more